

### Company Overview

We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid drug conjugate™ (PDCs™) delivery platform to develop PDCs that specifically target cancer cells to deliver improved efficacy and better safety as a result of fewer off-target effects. The PDC™ platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments and we plan to develop PDCs independently and through research and development collaborations.

### Cellecstar Reports Recent Corporate Highlights and 2018 First Quarter Financial Results

May 11 2018, 8:00 AM EDT

### Cellecstar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma

May 9 2018, 2:28 PM EDT

### Cellecstar Receives Rare Pediatric Disease Designation for CLR 131 to Treat Neuroblastoma

May 2 2018, 8:00 AM EDT

### Stock Overview

Symbol	CLRB
Exchange	NASDAQ
Market Cap	18.43m
Last Price	\$1.06
52-Week	\$1.03 - \$2.06

05/18/2018 04:00 PM EDT

### Investor Relations

LHA Investor Relations  
Miriam Weber Miller  
T: 212-838-3777  
[MMiller@lhai.com](mailto:MMiller@lhai.com)

### Management Team

#### James Caruso

President, CEO and Director

#### Dr. John Friend

Chief Medical Officer

#### Jarrold Longcor

Chief Business Officer

#### Brian M. Posner

Chief Financial Officer

---

### Cellecstar Biosciences, Inc.

3301 Agriculture Drive  
Madison, WI 53716

---

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.